From a non experts view, if the brain makes the decision, then if the part of the brain which controls this is disabled we will not feel pain. Hence developing a medication that will target the area which controls the pain. However with DDD if you control the pain you still have the problem of mobility.
I do not agree with your concluding comment, while the Phase I is more for safety the FDA will approve only a product if it passes safety and efficacy standards.
Back pain stem cell injection, page-129
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
-0.025(2.23%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.16 | $1.04 | $14.57M | 13.49M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 21024 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 241 | 1 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |